Maxygen, Inc. (NASDAQ:MAXY)
| CAPS Rating |
|
|---|---|
| Open | $5.62 |
| Previous Close | $5.67 |
| Daily Range | $5.49 - $5.67 |
| 52-Week Range | $3.97 - $6.20 |
| Market Cap | $163.04M |
| P/E Ratio | 1.30 |
| Dividend (Yield) | N/A (N/A) |
| Volume | 73,946 |
| Average Daily Volume | 0 |
MAXY
VS S&P 500 (SPY)
How do you think MAXY will perform against the market?
Caps
Motley Fool CAPS is a community working together to find better stocks and to become better investors.
MAXY Advanced Details
- CAPS Community Analysis: Commentary, Scorecard
- Advanced Financial Analysis: Historical Prices, Chart, Stats, Ratios, Earnings/Growth Rates, Statements, SEC Filings
MAXY News and Commentary
- Holy Share Buyback, Batman! – The Motley Fool
- Some Swings and Scalps for Today – Blog at The Motley Fool
- Whitney Tilson's 17 Newest Stock Picks From February: Part 2 – SeekingAlpha
- The World's Most-Watched Biotech – The Motley Fool
- Tiny Company, Tons of Cash – The Motley Fool
- A year in review – Blog at The Motley Fool
- GlaxoSmithKline Sells Entire Shareholding In Maxygen – SmartMoney
- A Back-Door Biofuel Investment – The Motley Fool
- Comments on Joel Greenblatt's Presentation to Value Investing Congress 2009 – Blog at The Motley Fool
- These 5 Stocks Have a Little Magic – The Motley Fool
- A Magic Formula Stock to Avoid: Maxygen (MAXY) – Blog at The Motley Fool
- Get Ready for the Fall? – The Motley Fool
- Surprising Low-Rated Stocks the Leaders Love – The Motley Fool
- Contrarian Shopping List – The Motley Fool
- Wall Street's Wish List – The Motley Fool
Related News and Articles
- Illuminating the Way Forward for Genomics – The Motley Fool
- When Passing Your Clinical Trial Isn't Enough – The Motley Fool
- This Just In: More Upgrades and Downgrades – The Motley Fool
RSS Headlines
Fool UK
